FDA Reviews Kura's NDA For Ziftomenib To Treat Acute Myeloid Leukemia With NPM1 Mutation

The FDA has accepted Kura Oncology's New Drug Application for ziftomenib as a treatment for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation, granting Priority Review with a PDUFA target date of November 30, 2025. The NDA is based on statistically significant results from the Phase 2 KOMET-001 trial, which met its primary endpoint of complete remission plus CR with partial hematological recovery. Ziftomenib was well-tolerated in the trial, demonstrating a favorable benefit-risk profile.

Analysis

Kura Oncology (KURA) has achieved a significant regulatory milestone with the U.S. Food and Drug Administration's (FDA) acceptance of its New Drug Application (NDA) for ziftomenib, targeting adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring a nucleophosmin 1 (NPM1) mutation. The FDA's decision to grant Priority Review status and assign a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025, underscores the potential clinical importance of ziftomenib, a development reflected in the strongly positive sentiment score of 0.9 for KURA. The NDA submission is robustly supported by results from the Phase 2 KOMET-001 registrational trial, which successfully met its primary endpoint—complete remission plus complete remission with partial hematological recovery (CR + CRh)—with statistical significance. Furthermore, ziftomenib demonstrated a favorable safety profile in the trial, being well-tolerated with limited myelosuppression and a low 3% discontinuation rate attributed to ziftomenib-related adverse events, leading to a highly encouraging benefit-risk assessment. This progress, achieved in collaboration with Kyowa Kirin Co., Ltd., marks a critical step towards potential full approval and subsequent market entry for ziftomenib, addressing an unmet need in a genetically defined AML patient population.

Key Decisions for Investors

• Recognize the FDA's NDA acceptance and Priority Review for ziftomenib as a significant de-risking event for Kura Oncology, enhancing the prospects for this key AML therapeutic candidate.
• Monitor Kura Oncology closely leading up to the November 30, 2025 PDUFA target date, as this represents a crucial, albeit medium-term, stock-specific catalyst.
• Assess the positive implications of the strong Phase 2 KOMET-001 trial data, which met its primary endpoint with statistical significance and showed good tolerability, on the likelihood of ziftomenib's approval and its potential competitive positioning.
• Evaluate Kura's forthcoming commercialization strategy for ziftomenib within the NPM1-mutant AML market segment, should regulatory approval be granted.